Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMISE Study (Breastfeeding Version)
NCT01061151Phase 3Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2011
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, open-label trial of lopinavir + ritonavir and emtricitabine + tenofovir disoproxil in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Started Mar 2011; status: completed.
02
Drugs
lopinavir + ritonaviremtricitabine + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT01061151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01061151.